Earnings ·
Valneva SE reported total revenues of €65.8 million for the six months ended June 30, 2026, a decline from €97.6…
VALNValneva SE
Valneva SE reported total revenues of €65.8 million for the six months ended June 30, 2026, a decline from €97.6 million in the prior year period, driven by lower product sales and discontinued third-party distribution. The company recorded a net loss of €63.3 million compared to a €20.8 million loss previously. Product sales totaled €64.0 million, with IXIARO/JESPECT generating €44.0 million and DUKORAL €14.7 million; IXCHIQ sales fell to €4.4 million amid negative gross margins due to inventory impairments and manufacturing contract termination costs of €9.7 million. Valneva completed an €84 million reserved offering in April 2026, receiving €37 million upfront with up to €47 million contingent on warrant exercises. The company initiated a restructuring program targeting a 10-15% workforce reduction and announced plans to sell its Saint-Herblain site for €6.2 million. Additionally, Valneva voluntarily withdrew its U.S. BLA application for IXCHIQ in January 2026 following FDA safety concerns. The company operates as a specialty vaccine developer and manufacturer focused on infectious diseases.